Follow The Filings

VTRS Viatris Inc.

Health Care, filed as VIATRIS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 2 managers in 2026 Q2, sold by 1

  • 4 Owners
  • Max 5.1%
  • $1.4B
  • 2 add 2 small

In 2026 Q2 Glenview Capital Management and David Einhorn added to Viatris.

Who owns this now

Largest portfolio weights among holders, up to 5.1% (Christopher Davis, Davis Selected Advisers). Not free-float ownership.

  1. Christopher Davis Reduce 5.1%
  2. Glenview Capital Management Add 2.9%
  3. Bill Miller Add 2.8%
  4. David Einhorn Add 1.1%

Who owns VTRS

Sorted by value, long equity only, as of 2026 Q2.

History
Christopher Davis, Davis Selected Advisers 5.1% Small trim −3.8% 75,232,254 $1.2B History
Glenview Capital Management 2.9% Add +8.7% 9,877,409 $157M History
David Einhorn, DME Capital Management 1.1%, was 0.77% Add +52.6% 2,773,470 $44M History
Bill Miller, Miller Value Partners 2.8%, was 2.6% Small add +0.2% 733,164 $12M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by VTRS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All VTRS insider trades
  • $2,221 bought by 1 insider
  • $284K sold by 1 insider outside a trading plan
  • $810K sold by 1 insider under 10b5-1 plans
  1. Paul Campbell See Remarks
    Planned sale
    $810K 50,076 shares at $16.17 14% of stake
    Traded Jun 25 Filed Jun 26
  2. Paul Campbell See Remarks
    Sale
    $284K 21,350 shares at $13.28 5.5% of stake
    Traded Mar 23 Filed Mar 24
  3. David S Simmons Director
    Buy
    $5,202 499 shares at $10.42 +73% to stake
    Traded Aug 27, 2025–Nov 3, 2025 Filed Mar 10

Also filed in the last 12 months, not counted as buying or selling: 59 option exercises and 37 share withholdings for taxes.

Congress

2 members of Congress traded VTRS in the last three years: 2 buys and 2 sales. 5 members listed it in 2025 annual reports.

All Congress trades
  1. Gilbert Ray Cisneros, Jr. D-CA-31 Buy $1K–$15K Nov 18, 2025 filed Dec 15, 2025
  2. Robert P. Bresnahan, Jr. R-PA-8 Sell $1K–$15K Apr 8, 2025 filed May 8, 2025
  3. Gilbert Ray Cisneros, Jr. D-CA-31 Partial sale $1K–$15K Mar 31, 2025 filed Apr 7, 2025
  4. Robert P. Bresnahan, Jr. R-PA-8 Buy $1K–$15K Feb 25, 2025 filed Mar 27, 2025

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
8-K 1.01,8.01,9.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
SCHEDULE 13G —
8-K 2.02,8.01,9.01
10-Q
8-K 1.01,2.03,9.01
8-K 1.01,2.03,9.01
424B5
8-K 8.01,9.01
424B5
8-K 5.07
8-K 2.02,8.01,9.01
10-Q
SCHEDULE 13G/A —
8-K 5.02,7.01,9.01
SCHEDULE 13G —
DEF 14A
DEFA14A
SCHEDULE 13G/A —

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $15.39B $14.69B $14.25B
Gross profit $6.44B $5.62B $5.01B
Gross margin * 41.8% 38.3% 35.2%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $12.98B $9.52B $9.79B
Total non-current assets * $34.71B $31.98B $27.4B
Total assets $47.69B $41.5B $37.19B
Total current liabilities $7.78B $5.78B $7.09B
Total non-current liabilities * $19.44B $17.09B $15.39B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $2.8B $2.3B $2.32B
Cash from investing -$0.764B $1.8B -$0.428B
Cash from financing -$2.3B -$4.33B -$1.29B
Net change in cash -$268.9M -$257.5M $611.9M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.